- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
EMA Invites Comments on Good Biomarker Practice
The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices.
The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices.
The outcome of the consultation will inform a guideline, which will set criteria to underpin the generation of robust clinical genomic datasets throughout a medicine’s lifecycle, the choice of genomic techniques and biomarkers, the impact on the relevant study design, and the appropriate level of analysis and reporting of genomic data. The goal is to enhance transparency, consistency, reproducibility and cross-validation between genomic-driven studies.
Comments on the paper are invited until October 31, 2014 and should be sent to pgwpsecretariat@ema.europa.eu.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
